---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-096071"
form_type: "8-K/A"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2025-10-02T23:59:59+00:00"
generated_at: "2026-05-17T04:55:21.282685+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# KALA halts pipeline, cuts 51% of staff, grants retention bonuses to top executives

## Summary
- Ceased development of KPI-012 and stem cell platform; workforce reduced by ~19 employees (~51%).
- Expects ~$0.4M in restructuring costs (severance/benefits), substantially in Q4 2025.
- Entered retention agreements: CEO Todd Bazemore ($183,750), CFO Mary Reumuth ($136,250), CMO Kim Brazzell ($145,000).
- Company preserving cash while exploring strategic alternatives.

## SEC filing metadata
- accession: 0001104659-25-096071
- form_type: 8-K/A
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2025-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000110465925096071/0001104659-25-096071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000110465925096071/tm2527808d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-096071
- JSON: https://secwatch.observer/filing/0001104659-25-096071.json
- Plain text: https://secwatch.observer/filing/0001104659-25-096071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.